Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Sees Large Drop in Short Interest

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) saw a large decline in short interest in the month of July. As of July 15th, there was short interest totaling 76,263 shares, a decline of 87.3% from the June 30th total of 602,285 shares. Currently, 1.6% of the company’s stock are short sold. Based on an average daily volume of 1,095,213 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Investors Weigh In On Creative Medical Technology

An institutional investor recently bought a new stake in Creative Medical Technology stock. Jane Street Group LLC purchased a new stake in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned about 1.17% of Creative Medical Technology at the end of the most recent reporting period. 1.42% of the stock is currently owned by institutional investors.

Creative Medical Technology Trading Down 0.1%

CELZ stock traded down $0.00 during midday trading on Friday, reaching $0.81. The company had a trading volume of 97,253 shares, compared to its average volume of 10,137,199. The company has a 50 day moving average of $1.69 and a two-hundred day moving average of $1.92. The company has a market capitalization of $3.84 million, a P/E ratio of -0.38 and a beta of 1.89. Creative Medical Technology has a 1 year low of $0.78 and a 1 year high of $6.25.

Creative Medical Technology (NASDAQ:CELZ) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.01. On average, sell-side analysts anticipate that Creative Medical Technology will post -1.14 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Creative Medical Technology in a research report on Friday, May 22nd. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Creative Medical Technology presently has a consensus rating of “Reduce”.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.